WO2021230258A1 - 高レバウジオシドe含有ステビア植物体 - Google Patents
高レバウジオシドe含有ステビア植物体 Download PDFInfo
- Publication number
- WO2021230258A1 WO2021230258A1 PCT/JP2021/017955 JP2021017955W WO2021230258A1 WO 2021230258 A1 WO2021230258 A1 WO 2021230258A1 JP 2021017955 W JP2021017955 W JP 2021017955W WO 2021230258 A1 WO2021230258 A1 WO 2021230258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- plant
- present
- genetic
- base
- Prior art date
Links
- 241000544066 Stevia Species 0.000 title claims description 103
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 title 1
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 title 1
- 230000002068 genetic effect Effects 0.000 claims abstract description 240
- 108700028369 Alleles Proteins 0.000 claims abstract description 134
- 241000196324 Embryophyta Species 0.000 claims description 158
- 238000000034 method Methods 0.000 claims description 142
- 239000000284 extract Substances 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 28
- 238000012216 screening Methods 0.000 claims description 24
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical class O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 229940127557 pharmaceutical product Drugs 0.000 claims description 8
- 210000001938 protoplast Anatomy 0.000 claims description 4
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000002257 embryonic structure Anatomy 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000002703 mutagenesis Methods 0.000 claims description 3
- 231100000350 mutagenesis Toxicity 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 description 101
- 230000035772 mutation Effects 0.000 description 70
- 108091008146 restriction endonucleases Proteins 0.000 description 51
- 239000000047 product Substances 0.000 description 45
- 235000019202 steviosides Nutrition 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 27
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 21
- 229940013618 stevioside Drugs 0.000 description 21
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 21
- 239000000523 sample Substances 0.000 description 19
- 239000004383 Steviol glycoside Substances 0.000 description 16
- 235000019411 steviol glycoside Nutrition 0.000 description 16
- 229930182488 steviol glycoside Natural products 0.000 description 16
- 150000008144 steviol glycosides Chemical class 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000000354 decomposition reaction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 230000013011 mating Effects 0.000 description 5
- 238000010188 recombinant method Methods 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000954177 Bangana ariza Species 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000003471 mutagenic agent Substances 0.000 description 4
- 231100000707 mutagenic chemical Toxicity 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000012225 targeting induced local lesions in genomes Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000001196 time-of-flight mass spectrum Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- -1 RevE Chemical class 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000010165 autogamy Effects 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011880 melting curve analysis Methods 0.000 description 2
- 230000021332 multicellular organism growth Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- QSIDJGUAAUSPMG-CULFPKEHSA-N steviolmonoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QSIDJGUAAUSPMG-CULFPKEHSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 1
- 108010061979 CEL I nuclease Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- OMHUCGDTACNQEX-OSHKXICASA-N Steviolbioside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OMHUCGDTACNQEX-OSHKXICASA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- JLPRGBMUVNVSKP-AHUXISJXSA-M chembl2368336 Chemical compound [Na+].O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C([O-])=O)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O JLPRGBMUVNVSKP-AHUXISJXSA-M 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000009401 outcrossing Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229930188195 rebaudioside Natural products 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/10—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits
- A01H1/101—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine or caffeine
- A01H1/102—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine or caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/10—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits
- A01H1/101—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine or caffeine
- A01H1/102—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine or caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
- A01H1/103—Non-starch polysaccharides, e.g. cellulose, fructans or levans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H4/00—Plant reproduction by tissue culture techniques ; Tissue culture techniques therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/10—Seeds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/12—Leaves
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/14—Asteraceae or Compositae, e.g. safflower, sunflower, artichoke or lettuce
- A01H6/1488—Stevia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/36—Terpene glycosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/13—Plant traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a stevia plant having a high content of rebaugioside E and a screening method thereof.
- Patent Document 1 discloses a functional sweetening composition containing a vitamin, a high-sweetness sweetening agent, and a sweetness improving composition.
- Steviol glycoside is known as a sweetening component contained in stevia extract.
- Stevia extract is mainly extracted and purified from Stevia leaves.
- Stevia is a perennial plant of the Asteraceae family that originates in Paraguay, South America, and its scientific name is Stevia Rebaudiana Bertoni. Since stevia contains a component having a sweetness of about 300 times or more that of sugar, this sweet component is extracted and cultivated for use as a natural sweetener.
- Rebaudioside A hereinafter, "Rebaudioside” may be abbreviated as "Reb"
- RebB RebC
- RebD RebE
- RebM RebM
- RebA has been evaluated as a sweetener having a high degree of sweetness and a high-quality sweetness, and is widely used.
- Other steviol glycosides are also being found to have their own sweetness and associated taste.
- the present invention provides a Stevia plant having a specific single nucleotide polymorphism (SNP) in the genomic nucleotide sequence, and a method for producing and screening the plant.
- SNP single nucleotide polymorphism
- the invention provides: [1] A Stevia plant having at least one of the following genetic characteristics (A) to (E).
- A It is homozygous or heterozygous for an allele in which the base at the position corresponding to the 40th position of SEQ ID NO: 1 is C.
- B Homozygous or heterozygous for alleles in which the base at the position corresponding to position 21 of SEQ ID NO: 2 is T.
- C Homozygous or heterozygous for alleles in which the base at the position corresponding to position 28 of SEQ ID NO: 3 is T.
- [5] The seed, dried leaf, tissue, tissue culture or cell of the plant according to any one of the above [1] to [4].
- [6] The tissue, tissue culture or cell according to [5] above, which is selected from embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections and callus.
- Rebaugioside E of 0.07% or more per unit mass of dried leaves, which comprises the step of crossing the Stevia plant according to any one of the above [1] to [4] with the second Stevia plant.
- a method for producing a stevia plant containing high rebaugioside E which comprises.
- a method for producing rebaugioside E which comprises a step of purifying rebaugioside E from the extract containing rebaugioside E according to the above [11].
- the plant extract according to any one of the above [1] to [4], the seed, dried leaf, tissue, tissue culture or cell extract according to the above [5], or the above [ 11] The step of providing the extract and the step of adding the extract to a food or drink, a sweetening composition, a fragrance or a raw material of a pharmaceutical product, which comprises a step of adding the extract to a food or drink, a sweetening composition, a fragrance or a pharmaceutical product. Production method.
- a method for screening a Stevia plant according to the description. (A) It is homozygous or heterozygous for an allele in which the base at the position corresponding to the 40th position of SEQ ID NO: 1 is C.
- C Homozygous or heterozygous for alleles in which the base at the position corresponding to position 28 of SEQ ID NO: 3 is T.
- FIG. 1 is a diagram showing a mutation (A) in the base sequence of SEQ ID NO: 16.
- the base enclosed in the frame is the base related to the mutation (A).
- FIG. 2 is a diagram showing a mutation (B) in the base sequence of SEQ ID NO: 20.
- the base enclosed in the frame is the base related to the mutation (B).
- FIG. 3 is a diagram showing a mutation (C) in the base sequence of SEQ ID NO: 24.
- the base enclosed in the frame is the base related to the mutation (C).
- FIG. 4 is a diagram showing a mutation (D) in the base sequence of SEQ ID NO: 28.
- the base enclosed in the frame is the base related to the mutation (D).
- FIG. 5 is a diagram showing a mutation (E) in the base sequence of SEQ ID NO: 32.
- the base enclosed in the frame is the base related to the mutation (E).
- the relationship between the genetic feature (A) and the average RevE content in the examples is shown. It is a figure which showed the result of having analyzed whether or not a Stevia plant has a genetic feature (A) by the dCAPS method.
- Lane 1 is homozygous for alleles with mutation (A)
- lane 2 is heterozygous for alleles with mutation (A)
- lane 3 is homozygous for alleles without mutation (A).
- the electrophoretic images of the samples obtained by treating the DNA of an individual with the limiting enzyme RsaI are shown.
- the present invention is derived from a wild species Stevia plant, and "at least one of the following genetic features (A) to (E) (hereinafter, at least one of the genetic features (A) to (E)".
- a Stevia plant having sometimes collectively referred to as “genetic characteristics of the present invention" (hereinafter, may be collectively referred to as "the plant of the present invention” or “the Stevia plant of the present invention”).
- the allele at which the base corresponding to the 40th position of SEQ ID NO: 1 is C is homozygous or heterozygous (hereinafter, may be referred to as "genetic feature (A) of the present invention”). ..
- the Stevia plant of the present invention has the genetic feature (A) of the present invention.
- the Stevia plant of the present invention is genetically homozygous for an allele in which the base corresponding to position 40 of SEQ ID NO: 1 is C in the genetic feature (A) of the present invention. It has characteristics (hereinafter, may be referred to as "genetic characteristics (A') of the present invention").
- a genetic feature that is heterozygous for an allele in which the base at the position corresponding to position 40 of SEQ ID NO: 1 is C may be referred to as a genetic feature (A ′′) of the present invention.
- the genetic feature (B) of the present invention is a genetic feature homozygous for an allele in which the base corresponding to the 21st position of SEQ ID NO: 2 is T (hereinafter, "genetic feature (B) of the present invention”. ') ” May be referred to.) Is preferable.
- a genetic feature that is heterozygous for an allele in which the base at the position corresponding to position 21 of SEQ ID NO: 2 is T may be referred to as a genetic feature (B ′′) of the present invention.
- the genetic feature (C) of the present invention is a genetic feature homozygous for an allele in which the base corresponding to position 28 of SEQ ID NO: 3 is T (hereinafter, "genetic feature (C) of the present invention”.
- a genetic feature that is heterozygous for an allele in which the base at the position corresponding to position 28 of SEQ ID NO: 3 is T may be referred to as a genetic feature (C ′′) of the present invention.
- the genetic feature (D) of the present invention is a genetic feature homozygous for an allele in which the base corresponding to position 59 of SEQ ID NO: 4 is C (hereinafter, "genetic feature (D) of the present invention". ') ” May be referred to.) Is preferable.
- a genetic feature that is heterozygous for an allele in which the base at the position corresponding to position 59 of SEQ ID NO: 4 is C may be referred to as a genetic feature (D ′′) of the present invention.
- the genetic feature (E) of the present invention is a genetic feature homozygous for an allele in which the base corresponding to position 64 of SEQ ID NO: 5 is T (hereinafter, "genetic feature (E) of the present invention”. ') ” May be referred to.) Is preferable.
- the genetic feature that is heterozygous for the allele in which the base at the position corresponding to position 64 of SEQ ID NO: 5 is T may be referred to as the genetic feature (E ′′) of the present invention.
- the plant of the present invention may have a plurality of the above genetic characteristics.
- the number of genetic features may be any of 2-5, ie 2, 3, 4 or 5.
- the combination of genetic features is not particularly limited and includes, for example, each combination in parentheses below: (A, B), (A, C), (A, D), (A, E), (B, C).
- the plant of the present invention has a genetic feature (A). In a more preferred embodiment, the plant of the present invention has a genetic feature (A'). In another preferred embodiment, the plant of the present invention has a genetic feature (A) and at least one of the genetic features (B)-(E), and in a more preferred embodiment, the present invention.
- the plant of (A) has a genetic feature (A) and has all of the genetic features (B) to (E). In another preferred embodiment, the plant of the present invention has a genetic feature (A) and at least one of the genetic features (B)-(D), and in a more preferred embodiment, the present invention.
- the plant of (A) has a genetic feature (A) and has all of the genetic features (B) to (D).
- the plant of the present invention has a genetic feature (A') and has at least one of the genetic features (B)-(E), and in a more preferred embodiment, the present invention.
- the plant of the present invention has a genetic feature (A') and has all of the genetic features (B) to (E).
- the plant of the present invention has a genetic feature (A') and has at least one of the genetic features (B)-(D), and in a more preferred embodiment, the present invention.
- the plant of the present invention has a genetic feature (A') and has all of the genetic features (B) to (D).
- the plant of the present invention has a genetic feature (A') and has at least one of the genetic features (B') to (E'), in a more preferred embodiment.
- the plant of the present invention has a genetic characteristic (A') and has all of the genetic characteristics (B') to (E').
- the plant of the present invention has a genetic feature (A') and has at least one of the genetic features (B') to (D'), in a more preferred embodiment.
- the plant of the present invention has a genetic feature (A') and has all of the genetic features (B') to (D').
- the "position corresponding to” means a position in the sequence (for example, the 40th position) existing in the genome when the same sequence as the reference sequence (for example, SEQ ID NOs: 1 to 5 etc.) exists in the genome. , 21st, 28th, 59th, 64th, etc.), and if the same sequence as the reference sequence does not exist in the genome, the position in the reference sequence in the sequence corresponding to the reference sequence in the genome. It means the position corresponding to. Whether or not a sequence equal to or equivalent to the reference sequence exists in the genome is determined by, for example, amplifying the genomic DNA of the target Stevia plant with a primer capable of amplifying the reference sequence by PCR and sequencing the amplification product.
- Non-limiting examples of the sequence corresponding to the reference sequence include, for example, 60% or more, 70% or more, 75% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more with respect to the reference sequence.
- the position corresponding to the position in the reference sequence in the sequence corresponding to the reference sequence in the genome can be determined in consideration of the base sequences before and after the position in the reference sequence. For example, by aligning the reference sequence with the sequence corresponding to the reference sequence in the genome, the position corresponding to the position in the reference sequence in the sequence corresponding to the reference sequence in the genome can be determined.
- the genome of the Stevia plant has a portion having the same base sequence as SEQ ID NO: 1. If so, the "position corresponding to the 40th position of SEQ ID NO: 1" is the 40th position from the 5'side of the portion having the same base sequence as SEQ ID NO: 1 in the genome.
- the genome of the Stevia plant is not the same as SEQ ID NO: 1 but has a portion having a base sequence corresponding to this, the genome does not have a portion having the same base sequence as SEQ ID NO: 1.
- the "position corresponding to the 40th position of SEQ ID NO: 1" does not necessarily correspond to the 40th position from the 5'side of the portion corresponding to the SEQ ID NO: 1, but the base sequence before and after the 40th position of the SEQ ID NO: 1 is used. With consideration, it is possible to identify the "position corresponding to the 40th position of SEQ ID NO: 1" in the genome of such a Stevia plant. For example, by aligning the base sequence of the portion corresponding to SEQ ID NO: 1 in the genome of the Stevia plant with the base sequence of SEQ ID NO: 1, "the position corresponding to the 40th position of SEQ ID NO: 1" in the genome of the Stevia plant. Can be identified.
- each position of the above (A) to (E) is referred to as "polymorphic site (A) of the present invention", “polymorphic site (B) of the present invention”, or “mutation site (A) of the present invention”. , "Variation site (B) of the present invention” and the like.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 1" is, for example, 60% or more, 70% or more, 75% or more, 80% or more, 81% or more, 82% or more with respect to the base sequence of SEQ ID NO: 1. 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% 96% or more, 97% or more, 98% or more, 98.1% or more, 98.4% or more, 98.7% or more, 99% or more, 99.2% or more, 99.5% or more or 99. It means a portion consisting of a base sequence having 8% or more sequence identity.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 1" includes the mutation site (A) from the 5'end to the 39th position of SEQ ID NO: 1 (that is, from the 5'end of SEQ ID NO: 1). ), A forward primer that hybridizes to the complementary sequence of the portion of 1 base (up to the base on the 5'end side), and positions 1 to 163 from the 3'end side of SEQ ID NO: 1 (that is, from the 3'end of SEQ ID NO: 1). It contains a portion of the Stevia plant genome that can be amplified by PCR with a reverse primer that hybridizes to the portion of the mutation site (A) up to the 1st base 3'end side base).
- the genetic feature (A) of the present invention has been described as an example, but the same applies to the genetic feature (B) to (E) of the present invention.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 1" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 6 and a reverse primer containing the base sequence of SEQ ID NO: 7. Contains parts of the Stevia plant genome that can be amplified by.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 2" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 8 and a reverse primer containing the base sequence of SEQ ID NO: 9. Contains parts of the Stevia plant genome that can be amplified by.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 3" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 10 and a reverse primer containing the base sequence of SEQ ID NO: 11. Contains parts of the Stevia plant genome that can be amplified by.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 4" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 12 and a reverse primer containing the base sequence of SEQ ID NO: 13. Contains parts of the Stevia plant genome that can be amplified by.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 5" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 14 and a reverse primer containing the base sequence of SEQ ID NO: 15. Contains parts of the Stevia plant genome that can be amplified by.
- the "allele in which the base at position corresponding to position 40 of SEQ ID NO: 1 is C” comprises the base sequence of SEQ ID NO: 16, 17, 18 or 19.
- the "allele in which the base at position corresponding to position 21 of SEQ ID NO: 2 is T” comprises the base sequence of SEQ ID NO: 20, 21, 22 or 23.
- the "allele in which the base at position corresponding to position 28 of SEQ ID NO: 3 is T” comprises the base sequence of SEQ ID NO: 24, 25, 26 or 27.
- the "allele in which the base at position corresponding to position 59 of SEQ ID NO: 4 is C” comprises the base sequence of SEQ ID NO: 28, 29, 30 or 31.
- the "allele in which the base at position corresponding to position 64 of SEQ ID NO: 5 is T" comprises the base sequence of SEQ ID NO: 32, 33, 34 or 35.
- each of the above mutations (A) to (E) can be referred to as “polymorphism (A) of the present invention", “polymorphism (B) of the present invention”, or “variation (A) of the present invention", “the present invention”. It may be referred to as “mutation of invention (B)” or the like.
- the above genetic features are PCR method, TaqMan PCR method, sequence method, microarray method, invader method, TILLING method, RAD (random amplified polymorphic DNA) method, restriction enzyme fragment length polymorphism (RFLP) method, PCR-SCSP method.
- AFLP amplified fragment length polymorphism
- SSLP simple sequence length polymorphism
- CAPS cleaved amplified polymorphic sequence
- dCAPS derived cleaved amplified polymorphic sequence
- ASO allele-specific oligonucleotide
- ARMS Modifier concentration gradient gel electrophoresis
- DGGE Modifier concentration gradient gel electrophoresis
- CCM chemical clairavage of mismatch
- DOL method MALDI-TOF / MS method
- TDI method Padlock probe method
- molecular beacon method DASH (dynamic allele specific hybridization) Method
- UCAN method ECA method
- PINPOINT method PROBE (primer oligonucleotide base extension) method
- VSET very short extension
- the genetic features of the invention can be detected with the following combinations of primer sets and restriction enzymes.
- the candidate plant has the mutation (A)
- PCR is performed on the genomic DNA of the candidate plant using a forward primer having the base sequence shown in SEQ ID NO: 36 and a reverse primer having the base sequence shown in SEQ ID NO: 37. Even if amplification is performed and the obtained PCR product (about 203 bp length, for example, SEQ ID NO: 38) is treated with the restriction enzyme RsaI, only a band with a length of about 203 bp (for example, SEQ ID NO: 38) is obtained.
- the candidate plant does not have the mutation (A) (the base at the position corresponding to the 40th position of SEQ ID NO: 1 is T)
- PCR amplification is performed in the same manner as above, and the obtained PCR product (about 203 bp) is performed.
- Treatment of the length, eg, SEQ ID NO: 39) with the restriction enzyme RsaI gives a band with a length of about 40 bp (eg, SEQ ID NO: 40) and a band with a length of about 163 bp (eg, SEQ ID NO: 41).
- FIG. 7 shows an example in which the mutation (A) is detected by the above method.
- a band with a length of about 203 bp derived from a non-degraded product is observed by the above dCAPS method, it can be determined that the band has the genetic feature (A) of the present invention.
- the genetic feature (A') of the present invention is observed. Can be determined to have.
- the genetic feature (A'') of the present invention is defined. Can be determined to have.
- PCR is performed on the genomic DNA of the candidate plant using a forward primer having the base sequence shown in SEQ ID NO: 42 and a reverse primer having the base sequence shown in SEQ ID NO: 43.
- amplification was performed and the resulting PCR product (approximately 364 bp length, eg, SEQ ID NO: 44) was treated with the restriction enzyme AclI, a band approximately 18 bp long (eg, SEQ ID NO: 46) and a band approximately 346 bp long (eg, sequence). Number 47) is obtained.
- PCR amplification may be performed in the same manner as described above, and the obtained PCR product (about 364 bp length, for example, SEQ ID NO: 45) may be treated with the restriction enzyme AclI. Only a band with a length of 364 bp (eg, SEQ ID NO: 45) can be obtained. Therefore, if a band having a length of about 18 bp and / or a band having a length of about 346 bp derived from the decomposition product is recognized by the above dCAPS method, it can be determined that the product has the genetic feature (B) of the present invention.
- the genetic feature (B') of the present invention is exhibited. Can be determined to have.
- the genetic feature (B ′′) of the present invention is defined. Can be determined to have.
- PCR is performed on the genomic DNA of the candidate plant using a forward primer having the base sequence shown in SEQ ID NO: 48 and a reverse primer having the base sequence shown in SEQ ID NO: 49.
- amplification was performed and the resulting PCR product (approximately 353 bp long, eg, SEQ ID NO: 50) was treated with the restriction enzyme AluI, a band approximately 19 bp long (eg, SEQ ID NO: 52) and a band approximately 334 bp long (eg, sequence). The number 53) is obtained.
- PCR amplification may be performed in the same manner as described above, and the obtained PCR product (about 353 bp length, for example, SEQ ID NO: 51) may be treated with the restriction enzyme AluI. Only 353 bp long bands (eg, SEQ ID NO: 51) can be obtained. Therefore, if a band having a length of about 19 bp and / or a band having a length of about 334 bp derived from the decomposition product is recognized by the above dCAPS method, it can be determined that the product has the genetic feature (C) of the present invention.
- the genetic feature (C') of the present invention is exhibited. Can be determined to have.
- the genetic feature (C ′′) of the present invention is defined. Can be determined to have.
- PCR is performed on the genomic DNA of the candidate plant using a forward primer having the base sequence shown in SEQ ID NO: 54 and a reverse primer having the base sequence shown in SEQ ID NO: 55.
- amplification was performed and the obtained PCR product (approximately 349 bp length, eg, SEQ ID NO: 56) was treated with the restriction enzyme AluI, a band approximately 21 bp long (eg, SEQ ID NO: 58) and a band approximately 328 bp long (eg, sequence). Number 59) is obtained.
- PCR amplification may be performed in the same manner as described above, and the obtained PCR product (about 349 bp length, for example, SEQ ID NO: 57) may be treated with the restriction enzyme AluI. Only a band with a length of 349 bp (eg, SEQ ID NO: 57) can be obtained. Therefore, if a band having a length of about 21 bp and / or a band having a length of about 328 bp derived from the decomposition product is recognized by the above dCAPS method, it can be determined that the product has the genetic feature (D) of the present invention.
- the genetic feature (D') of the present invention is exhibited. Can be determined to have.
- the genetic feature (D ′′) of the present invention is defined. Can be determined to have.
- PCR is performed on the genomic DNA of the candidate plant using a forward primer having the base sequence shown in SEQ ID NO: 60 and a reverse primer having the base sequence shown in SEQ ID NO: 61.
- amplification was performed and the obtained PCR product (approximately 349 bp length, eg, SEQ ID NO: 62) was treated with the restriction enzyme AluI, a band approximately 21 bp long (eg, SEQ ID NO: 64) and a band approximately 328 bp long (eg, sequence). The number 65) is obtained.
- PCR amplification may be performed in the same manner as described above, and the obtained PCR product (about 349 bp length, for example, SEQ ID NO: 63) may be treated with the restriction enzyme AluI. Only a band with a length of 349 bp (eg, SEQ ID NO: 63) can be obtained. Therefore, if a band having a length of about 21 bp and / or a band having a length of about 328 bp derived from the decomposition product is recognized by the above dCAPS method, it can be determined that the product has the genetic feature (E) of the present invention.
- the genetic feature (E') of the present invention is exhibited. Can be determined to have.
- the genetic feature (E'') of the present invention is defined. Can be determined to have.
- restriction enzyme treatment can be performed according to the conditions recommended by the distributor of each restriction enzyme to be used.
- the mutation sites (A) to (E) of the present invention are in a state of linkage disequilibrium because their positions on the genome are close to each other within 173 bp. Therefore, if the plant of the present invention has any of the genetic characteristics (A) to (E), it tends to have other genetic characteristics (A) to (E) as well. .. If the plant of the present invention has any of the genetic features (A') to (E'), it tends to have other genetic features (A') to (E') as well. There is.
- the stevia plant having the genetic characteristics of the present invention has a chemical characteristic that it contains 0.07% or more of RebE per unit mass of dried leaves.
- RebE has a high sweetness ratio, for example, has a sweetness ratio of 1.5 times or more that of stevioside, and is known to have good taste quality. It is also said to be highly soluble and stable.
- a sweetener containing RebE is expected as a sweetener having a good mouthfeel and taste. Therefore, Stevia plants having a high RebE content are expected.
- the presence of the genetic features (A) to (E) of the present invention is highly related to the presence of the chemical features of the present invention. Therefore, a Stevia plant having at least one of the genetic characteristics (A) to (E) of the present invention is likely to have the chemical characteristics of the present invention, and the genetic characteristics (A) to (E) of the present invention. It is also possible to screen Stevia plants having the chemical characteristics of the present invention using at least one of (E) as an index.
- the content of RebE is 0.07% or more per unit mass of dried leaves, for example, at a ratio of 0.07% by mass or more to a predetermined mass of dried leaves (for example, 50 mg). It means that RebE (for example, 0.035 mg or more) is contained.
- the ratio of RevE per unit mass of dried leaves in this embodiment is not limited, for example, 0.07% or more, more than 0.10%, 0.15% or more, more than 0.49%, 0.
- the upper limit of the ratio of RebE per unit mass of dried leaves is not particularly limited, but may be, for example, 20%, 15%, 10%, 7% or the like.
- the dried leaf means a leaf having a water content reduced to 3 to 4% by weight by drying the fresh leaf of the Stevia plant of the present invention.
- the plant of the present invention has a mass ratio of RebE of 0.5% or more to total steviol glycoside (TSG).
- TSG total steviol glycoside
- the total mass of RebE contained in a leaf for example, dried leaf or fresh leaf
- RebE / TSG% as a ratio to the total mass of steviol glycoside obtained from the leaf
- the value of RebE / TSG in this embodiment is not limited, and is, for example, 0.5% or more, 1.5% or more, 2.0% or more, 2.4% or more, 2.5% or more, 3.0.
- % Or more 3.5% or more, 4.0% or more, 4.5% or more, 5.0% or more, 5.5% or more, 6.0% or more, 6.5% or more, 7.0% or more , 7.5% or more, 8.0% or more, 8.5% or more, 9.0% or more, 9.5% or more, 10.0% or more, 15.0% or more, 20.0% or more, 22 It may be 0.4% or more, 25.0% or more, 25.5% or more, 30.0% or more, 33.5% or more, 35.0% or more, 40.0% or more, 45.0% or more. ..
- the upper limit of the mass ratio of RebE to TSG is not particularly limited, but may be, for example, 85%, 75%, 65%, 55%, or the like.
- TSG is a general term for measurable steviol glycosides, and does not include unknown steviol glycosides or steviol glycosides present in an amount below the detection limit.
- the TSGs are RebA, RebB, RebC, RebD, RebE, RebF, RebG, RebI, RebJ, RebK, RebM, RebN, RebO, RebQ, RebR, Zulcoside A, Rubusoside, Steviolmonoside, Steviolbioside and Any combination of two or more selected from the group consisting of stevioside.
- the TSG consists of RebA, RebB, RebC, RebD, RevE, RevF, RevG, RevM, RevN and stevioside.
- the plant of the present invention has a RevE / stevioside value of 1 or less.
- RevE / stevioside value of 1 or less.
- the value of RebE / stevioside is not limited, and may be, for example, 1 or less, 0.95 or less, 0.90 or less, 0.85 or less, 0.65 or less, and the like.
- the lower limit of RebE / stebioside is not particularly limited, but for example, 0.07 or more, 0.11 or more, 0.12 or more, 0.13 or more, 0.14 or more, 0.15 or more, 0.17 or more, 0.
- Steviol glycosides such as RebE and stevioside are extracted by reacting the fresh or dried leaves of the plant of the present invention with an appropriate solvent (aqueous solvent such as water or organic solvent such as alcohol, ether and acetone). Can be extracted in the state of.
- aqueous solvent such as water or organic solvent such as alcohol, ether and acetone
- ethyl acetate and other organic solvents water gradient, high performance liquid chromatography (HPLC), gas chromatography, time-of-flight mass analysis (Time-). Purification of individual steviol glycosides, such as RevE, by using known methods such as of-Flight mass spectrometry (TOF-MS), Ultra (High) Performance Liquid Chromatography (UPLC), etc. Can be done.
- TOF-MS high performance liquid chromatrometry
- UPLC Ultra (High) Performance Liquid Chromatography
- the content of steviol glycosides such as RebE and stevioside can be measured by the method described in Ohta et al. Or WO2010 / 038911 described above, or by the method described in Examples described later. Specifically, for example, fresh leaves can be sampled from the Stevia plant of the present invention and measured by performing LC-MS / MS.
- the plant of the present invention can be obtained by a non-genetical recombination method even if it is obtained by a gene recombination method or its descendants (hereinafter, may be referred to as "genetically recombinant plant”). It may be a plant or a progeny thereof (hereinafter, may be referred to as “non-genetically recombinant plant”).
- Examples of the "non-genetically recombinant method” include a method of inducing a mutation in a gene of a host cell (or a host plant) without introducing a foreign gene, in addition to crossing and self-fertilization. Such a method includes a method of allowing a mutagen to act on plant cells.
- EMS ethyl methanesulfonic acid
- sodium azide ethyl methanesulfonic acid
- EMS 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%
- Plant cells can be treated at a concentration such as 1.0%.
- the processing time is 1 to 48 hours, 2 to 36 hours, 3 to 30 hours, 4 to 28 hours, 5 to 26 hours, and 6 to 24 hours.
- the treatment procedure itself it can be carried out by immersing the water-absorbing seeds that have undergone the water absorption process in a treatment solution containing a mutagen at the above concentration for the above treatment time.
- the non-genetically recombinant method there is also a method of irradiating plant cells with radiation such as X-rays, ⁇ -rays, and ultraviolet rays.
- cells irradiated with an appropriate ultraviolet irradiation amount are cultured in a selective medium or the like, and then cells, curls, or plants having the desired trait are selected.
- the irradiation intensity at that time was 0.01 to 100 Gr, 0.03 to 75 Gr, 0.05 to 50 Gr, 0.07 to 25 Gr, 0.09 to 20 Gr, 0.1 to 15 Gr, 0.1 to 10 Gr, 0.
- the irradiation distance is 1 cm to 200 m, 5 cm to 100 m, 7 cm to 75 m, 9 cm to 50 m, 10 cm to 30 m, 10 cm to 20 m, 10 cm to 10 m, and the irradiation time is 1 minute to 2 minutes.
- the intensity, distance and time of irradiation vary depending on the radiation type and the state to be irradiated (cells, curls, plants), but can be appropriately adjusted by those skilled in the art.
- plant cells may be mutated during culture, so it is preferable to return them to individual plants for more stable trait maintenance.
- the plant body of the present invention includes not only the whole plant body but also plant organs (for example, leaves, petals, stems, roots, seeds, etc.), plant tissues (for example, epidermis, master, soft tissue, wood part, canal bundle, fence-like shape). Tissues, spongy tissues, etc.) or various forms of plant cells (eg, suspended cultured cells), protoplasts, leaf sections, curls, etc. may be included.
- the leaves may be dry leaves.
- the plant body of the present invention may also include cultured plant cells or tissue cultures. This is because plants can be regenerated by culturing such plant culture cells or tissue cultures. Examples of reproducible forms of the plant of the present invention include, but are limited to, embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections and callus. It's not a thing.
- the present invention comprises a step of crossing a Stevia plant of the present invention with a second Stevia plant, and the RebE of 0.07% by mass or more per dried leaf is included.
- a method for producing a Stevia plant hereinafter, may be referred to as "method for producing the present invention", which comprises.
- the Stevia plant produced by this method has the same phenotype and genetic characteristics as the plant of the present invention.
- the amount of RebE in the plant obtained by the production method of the present invention is the plant of the present invention. As described in the body section.
- the plant obtained by the production method of the present invention has a combination of each characteristic (chemical characteristic and / or genetic characteristic) described in the section of the plant of the present invention.
- crossing means that the plant body (first generation (S1)) of the present invention is crossed with the second plant body (S1), and the child plant body (the present invention) is crossed. It means to obtain a plant body (second generation (S2)) produced by the production method of the above.
- back-crossing means the plant body of the present invention and the second.
- the offspring plant (S2) born between the plant and the plant is further crossed with the plant of the present invention (that is, the plant having the genetic characteristics of the present invention) (S1) to carry out the genetic characteristics of the present invention. It is a method for producing a plant having the same. If the second plant (S1) used in the production method of the present invention has the same phenotype and genetic characteristics as the plant of the present invention, it is substantially. It becomes a crossing back to.
- the plant of the present invention can also be produced by self-fertilization.
- Self-propagation can be carried out by self-pollinating the pollen of the stamens of the plant of the present invention to the pistils of the plant of the present invention.
- the plant produced by the production method of the present invention has the same phenotype and genetic characteristics as the plant of the present invention, the plant produced by the production method of the present invention is further referred to as a third Stevia plant. It is also possible to produce a Stevia plant having a phenotype equivalent to that of the plant of the present invention by crossing with.
- the plant body of the present invention can also be produced by regenerating the plant body by culturing the tissue culture or cells described above.
- the culture conditions are the same as those for culturing wild-type stevia plant tissue cultures or plant culture cells, and are known (Protocols for In Vitro cultures and secondary metabolite analysis of aromatic and medicinal plants, Method in molecular biology, vol. 1391, pp113-123).
- the plant of the present invention can be produced by introducing the mutation of the present invention into the genome of the Stevia plant.
- the introduction of the mutation may be carried out by a genetically recombinant method or a non-genetically recombinant method.
- the non-genetically recombinant method is as described in the section of the plant body of the present invention.
- a plant of the present invention and a plant having the same phenotype and / or genetic characteristics as the plant of the present invention detect the genetic characteristics of the present invention from the tissue of the plant. This can be screened.
- screening means distinguishing between a plant of the present invention and a plant other than the present, and selecting the plant of the present invention.
- the invention comprises, in another aspect, the step of detecting the presence and / or absence of at least one of the genetic features (A)-(E) of the invention from the genome of the test plant.
- a method for screening (hereinafter, may be referred to as “the screening method of the present invention”) is provided.
- the genetic feature to be detected is at least one of the genetic features (A) to (E).
- the genetic feature to be detected is the genetic feature (A), more preferably the genetic feature (A').
- the genetic feature to be detected is at least one of the genetic feature (A) and the genetic feature (B)-(E), more preferably the genetic feature (A). All of the genetic characteristics (B)-(E).
- the genetic feature to be detected is at least one of the genetic feature (A) and the genetic feature (B)-(D), more preferably the genetic feature (A). All of the genetic characteristics (B)-(D).
- the genetic feature to be detected is at least one of the genetic feature (A') and the genetic feature (B)-(E), more preferably the genetic feature (A'). ) And all of the genetic features (B)-(E).
- the genetic feature to be detected is at least one of the genetic feature (A') and the genetic feature (B)-(D), more preferably the genetic feature (A'). ) And all of the genetic features (B)-(D).
- the genetic feature to be detected is at least one of a genetic feature (A') and a genetic feature (B')-(E'), more preferably a genetic feature ( A') and all of the genetic features (B')-(E').
- the genetic feature to be detected is at least one of a genetic feature (A') and a genetic feature (B') to (D'), more preferably a genetic feature ( A') and all of the genetic features (B')-(D').
- the remaining genetic features can be detected by detecting any one of them.
- the presence or absence of genetic features can be estimated.
- the screening method of the present invention may further include a step of selecting a plant in which the presence of at least one of the above genetic features is detected from among the test plants.
- the presence of the genetic feature (A') of the present invention can be determined, for example, by the presence of allele a alone.
- the presence of a genetic feature (A'') can be determined, for example, by the presence of both allele a and allele A.
- the presence of the genetic feature (B') of the present invention can be determined, for example, by the presence of only the allele b.
- the presence of a genetic feature (B'') can be determined, for example, by the presence of both allele b and allele B.
- the presence of the genetic feature (C') of the present invention can be determined, for example, by the presence of allele c alone.
- the presence of a genetic feature (C'') can be determined, for example, by the presence of both allele c and allele C.
- the presence of the genetic feature (D') of the present invention can be determined, for example, by the presence of only the allele d.
- the presence of a genetic feature (D'') can be determined, for example, by the presence of both allele d and allele D.
- the presence of the genetic feature (E') of the present invention can be determined, for example, by the presence of only the allele e.
- the presence of a genetic feature (E'') can be determined, for example, by the presence of both allele e and allele E.
- the absence of the genetic feature (A') of the present invention can be determined, for example, by the presence of allele A.
- the absence of a genetic feature (A'') can be determined, for example, by the presence of either allele A or allele a alone.
- the absence of the genetic feature (B') of the present invention can be determined, for example, by the presence of allele B.
- the absence of a genetic feature (B'') can be determined, for example, by the presence of either allele B or allele b alone.
- the absence of the genetic feature (C') of the present invention can be determined, for example, by the presence of allele C.
- the absence of a genetic feature (C'') can be determined, for example, by the presence of either allele C or allele c.
- the absence of the genetic feature (D') of the present invention can be determined, for example, by the presence of allele D.
- the absence of a genetic feature (D'') can be determined, for example, by the presence of either allele D or allele d alone.
- the absence of the genetic feature (E') of the present invention can be determined, for example, by the presence of the allele E.
- the absence of a genetic feature (E'') can be determined, for example, by the presence of either allele E or allele e.
- Specific examples of the method for detecting genetic features of the present invention include PCR method, TaqMan PCR method, sequencing method, microarray method, invader method, TILLING method, RAD method, RFLP method, PCR-SSCP method, AFLP method, and SSLP method.
- a primer such that the 3'end portion has a sequence complementary to the mutation site of the present invention.
- the primer designed in this way when the sample used as a template has the mutation of the present invention, the primer completely hybridizes to the template, so that the polymerase extension reaction proceeds, but the template is the mutation of the present invention.
- the nucleotide at the 3'end of the primer will be mismatched with the template and no extension reaction will occur. Therefore, if PCR amplification is performed using such a primer, the amplification product is analyzed by agarose gel electrophoresis or the like, and an amplification product of a predetermined size can be confirmed, the sample template has a mutation.
- the primer sequence is designed so that the mutation of the present invention does not overlap with the primer sequence and the gene mutation of the present invention can be amplified by PCR, and the base sequence of the amplified nucleotide fragment is sequenced.
- the genetic features of the present invention can be detected.
- PCR and agarose gel electrophoresis see: Sambrook, Fritsch and Maniatis, "Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press.
- the TaqMan PCR method is a method utilizing a fluorescently labeled allele-specific oligo and a PCR reaction with Taq DNA polymerase (Livak, KJ Genet. Anal. 14, 143 (1999); Morris T. et al., J. . Clin. Microbiol. 34, 2933 (1996)).
- the sequencing method is a method of analyzing the presence or absence of mutation by amplifying the region containing the mutation by PCR and sequencing the DNA sequence using Dye Terminator or the like (Sambrook, Fritsch and Maniatis, "Molecular Cloning:". A Laboratory Manual ”2nd Edition (1989), Cold Spring Harbor Laboratory Press).
- a DNA microarray is one in which one end of a nucleotide probe is fixed in an array on a support, and includes a DNA chip, a Gene chip, a microchip, a bead array, and the like. By using a probe containing a sequence complementary to the mutation site of the present invention, the presence or absence of the polymorphism of the present invention can be comprehensively detected.
- DNA microarray assays such as DNA chips include GeneChip assays (see Affymetrix; US Pat. Nos. 6,045,996, 5,925,525, and 5,858,659). GeneChip technology utilizes a miniaturized, high-density microarray of oligonucleotide probes attached to a chip.
- the invader method is a special end in which two types of reporter probes specific to each allele of a mutation such as SNP and one type of invader probe are hybridized to the template DNA, and the structure of the DNA is recognized and cleaved.
- a combination of DNA cleavage by a Cleavease enzyme with nuclease activity (Livak, KJ Biomol. Eng. 14, 143-149 (1999); Morris T. et al., J. Clin. Microbiol. 34, 2933 ( 1996); Lyamichev, V. et al., Science, 260, 778-783 (1993), etc.).
- the TILLING (Targeting Induced Local Lesions IN Genomes) method is a method for screening mutation mismatches in the genome of a mutant population into which a mutation has been introduced by PCR amplification and CEL I nuclease treatment.
- the genetic feature (A) of the present invention can be detected, for example, by the dCAPS method using the following primer set and restriction enzyme.
- ⁇ Primer set Complementary to a forward primer containing a contiguous sequence 15-39 bases long from the 3'end of SEQ ID NO: 36 and any contiguous 15 or more bases sequence located 3'from position 41 of SEQ ID NO: 1 or 16.
- a primer set containing a reverse primer containing a suitable sequence eg, SEQ ID NO: 37
- a primer set containing a reverse primer containing a sequence complementary to any contiguous sequence of 15 or more bases located 3'from position 22 of 84 eg, SEQ ID NO: 85.
- Restriction enzymes The restriction enzyme corresponding to the primer set based on SEQ ID NO: 36 contains RsaI, the restriction enzyme corresponding to the primer set based on SEQ ID NO: 81 contains Tsp45I, and the restriction enzyme corresponding to the primer set based on SEQ ID NO: 82 contains AciI.
- the genetic feature (B) of the present invention can be detected, for example, by the dCAPS method using the following primer set and restriction enzyme.
- ⁇ Primer set A forward primer containing a contiguous sequence 15-20 bases long from the 3'end of SEQ ID NO: 42, 86 or 87 and any contiguous 15 or more bases located 3'from position 22 of SEQ ID NO: 2 or 20.
- a primer set comprising a reverse primer containing a sequence complementary to the sequence (eg, SEQ ID NO: 43).
- Restriction enzymes The restriction enzyme corresponding to the primer set based on SEQ ID NO: 42 contains AclI, the restriction enzyme corresponding to the primer set based on SEQ ID NO: 86 contains AluI, and the restriction enzyme corresponding to the primer set based on SEQ ID NO: 87 contains PacI.
- the genetic feature (C) of the present invention can be detected, for example, by the dCAPS method using the following primer set and restriction enzyme.
- ⁇ Primer set A forward primer containing a contiguous sequence 15-20 bases long from the 3'end of SEQ ID NO: 48, 88 or 89 and any contiguous 15 or more bases located 3'from position 22 of SEQ ID NO: 50 or 51.
- a primer set comprising a reverse primer comprising a sequence complementary to the sequence (eg, SEQ ID NO: 49).
- Restriction enzymes The restriction enzyme corresponding to the primer set based on SEQ ID NO: 48 contains AluI, the restriction enzyme corresponding to the primer set based on SEQ ID NO: 88 contains BglI, and the restriction enzyme corresponding to the primer set based on SEQ ID NO: 89 contains ScaI.
- the genetic feature (D) of the present invention can be detected, for example, by the dCAPS method using the following primer set and restriction enzyme.
- ⁇ Primer set A forward primer containing a contiguous sequence 15-21 bases long from the 3'end of SEQ ID NO: 54, 90 or 91, and any contiguous 15 or more bases located 3'from position 23 of SEQ ID NO: 56 or 57.
- a primer set comprising a reverse primer comprising a sequence complementary to the sequence (eg, SEQ ID NO: 55).
- Restriction enzymes The restriction enzyme corresponding to the primer set based on SEQ ID NO: 54 contains AluI, the restriction enzyme corresponding to the primer set based on SEQ ID NO: 90 contains MboI, and the restriction enzyme corresponding to the primer set based on SEQ ID NO: 91 contains BglII.
- the genetic feature (E) of the present invention can be detected, for example, by the dCAPS method using the following primer set and restriction enzyme.
- ⁇ Primer set A forward primer containing a contiguous sequence 15-22 bases long from the 3'end of SEQ ID NO: 60, 92 or 93 and any contiguous 15 or more bases located 3'from position 24 of SEQ ID NO: 62 or 63.
- a primer set comprising a reverse primer comprising a sequence complementary to the sequence (eg, SEQ ID NO: 61).
- Restriction enzymes The restriction enzyme corresponding to the primer set based on SEQ ID NO: 60 contains AluI, the restriction enzyme corresponding to the primer set based on SEQ ID NO: 92 contains MboI, and the restriction enzyme corresponding to the primer set based on SEQ ID NO: 93 contains BglII.
- the primer sequence can be optimized within the range that satisfies the above conditions.
- optimization of primer design refer to, for example, Sambrook and Russell, “Molecular Cloning: A Laboratory Manual” 3rd Edition (2001), Cold Spring Harbor Laboratory Press, etc.
- Each of the above primers may have a length of 15 to 50 bases, a length of 18 to 48 bases, a length of 20 to 45 bases, a length of 30 to 40 bases, or the like.
- Restriction enzymes corresponding to each primer set also include other enzymes that recognize the same sequence as the above enzyme and cleave the same site, or isoschizomers of the above enzymes. It is also possible to design a primer set other than the above based on the genetic characteristics of the present invention and select a restriction enzyme corresponding to the primer set.
- the genetic features (A)-(E) of the present invention can be detected, for example, by the dCAPS method using a primer set having the following sequence and a restriction enzyme.
- the screening method of the present invention may further include the step of measuring the RebE content of the tissue (for example, leaves) of the test Stevia plant.
- the measurement of the content is as described in the section of the plant body of the present invention.
- an individual having a high content of RebE is selected and crossed with another Stevia plant to obtain a child.
- the screening method of the present invention may be applied to plants. Therefore, the screening method of the present invention may include the step of detecting the genetic feature of the present invention from the genome of the test Stevia plant, and may further include one or more of the following steps.
- a step of mating a selected individual having a high content of RebE with another Stevia plant (Iv) A step of detecting the genetic characteristics of the present invention from the genome of a child plant obtained by mating.
- V A step of measuring the RebE content of a child plant tissue in which the genetic feature of the present invention is detected
- (Vi) A step of selecting an individual having a high RebE content from among the seedlings in which the genetic characteristics of the present invention have been detected.
- the screening method of the present invention may include one or more of the following steps.
- (Iv') A step of detecting the genetic features of the present invention from the genome of a child plant obtained by mating.
- (V') A step of measuring the content of stevioside or TSG in a plant tissue in which the genetic feature of the present invention is detected,
- (Vi') A step of selecting an individual having a high mass ratio of RebE to RevE / stevioside or TSG from among the seedlings in which the genetic characteristics of the present invention have been detected.
- RebE / stevioside or TSG mass ratio to select include, for example, the RebE content, RebE / stevioside or among the test Stevia plants in which the genetic features of the invention have been detected.
- the height of the mass ratio of RebE to TSG the top 50%, the top 40%, the top 30%, the top 20%, the top 10%, the top 5%, the top 4%, the top 3%, It may be an individual up to the top 2% or the top 1%.
- other Stevia plants to be crossed may or may not contain the genetic features of the present invention.
- the steps (iii) to (vi) or the steps (iii') to (vi') can be repeated a plurality of times. In this way, Stevia plants with higher RebE content, RebE / stevioside or RebE mass ratio to TSG can be screened.
- the test Stevia plant may be a natural Stevia plant or a non-genetically modified Stevia plant.
- the non-genetically modified Stevia plant is as described in the section of the plant of the present invention.
- the test Stevia plant may include Stevia plants that have undergone mutagenesis treatment and progeny plants thereof.
- the induction of the mutation is as described in the section of the plant body of the present invention, and includes treatment with a mutagen, treatment with radiation or light irradiation, and the like.
- the amount of RebE, the amount of stevioside, the amount of RebE relative to the amount of TSG, etc. in the plant obtained by the screening method of the present invention are as described in the section of the plant of the present invention.
- the present invention also provides the primer sets and combinations thereof described above, for example, the primer sets shown in Tables 1 to 5 above, and combinations of these primer sets.
- the present invention further relates to a primer set capable of amplifying a region having a base sequence selected from the group consisting of SEQ ID NOs: 1 to 5, 16, 20, 24, 28 and 32 by PCR, for example, the base sequence of SEQ ID NO: 6.
- Primer set of a forward primer containing the nucleotide sequence of SEQ ID NO: 7 and a reverse primer containing the nucleotide sequence of SEQ ID NO: 7 a primer set of a forward primer containing the nucleotide sequence of SEQ ID NO: 8 and a reverse primer containing the nucleotide sequence of SEQ ID NO: 9, SEQ ID NO:
- Provided is a set, a primer set of a forward primer containing the base sequence of SEQ ID NO: 14, and a reverse primer containing the base sequence of SEQ ID NO: 15.
- the present invention provides a probe (hereinafter, may be referred to as "probe of the present invention") capable of detecting the presence and / or absence of a genetic feature of the present invention.
- the probe of the present invention may have a structure suitable for various detection methods (for example, real-time PCR method such as TaqMan PCR method) in which the genetic features of the present invention are present and / or absent.
- the probe of the present invention may contain a base sequence having complementarity to a portion of the genome containing the mutation site of the present invention.
- Non-limiting examples of such probes include sequences having complementarity to the base sequence selected from SEQ ID NOs: 17-19, 21-23, 25-27, 29-31, 33-35, 66-80. Can be mentioned.
- SEQ ID NOs: 17-19, 21-23, 25-27, 29-31, 33-35 are specific for alleles containing the mutations of the present invention
- SEQ ID NOs: 66-80 are the present invention. It is specific to alleles that do not contain mutations in.
- SEQ ID NOs: 17 to 19 are specific to allele a
- SEQ ID NOs: 21 to 23 are specific to allele b
- SEQ ID NOs: 25 to 27 are specific to allele c
- SEQ ID NOs: 29 to 31 are specific to allele c.
- SEQ ID NOs: 33 to 35 are specific to allele e.
- SEQ ID NOs: 66 to 68 are specific to allele A
- SEQ ID NOs: 69 to 71 are specific to allele B
- SEQ ID NOs: 72 to 74 are specific to allele C
- SEQ ID NOs: 75 to 77 are specific.
- Allele D is specific
- SEQ ID NOs: 78-80 are specific to Allele E.
- the presence of the genetic features (A) to (E) of the present invention is the detection of only the allele containing the mutation of the present invention, or both the detection of the allele containing the mutation of the present invention and the allele containing no mutation of the present invention.
- the absence of the genetic features (A) to (E) of the present invention can be detected by detecting only the alleles containing no mutation of the present invention.
- the presence of the genetic features (A') to (E') of the present invention can be detected by detecting only the allele containing the mutation of the present invention, and the genetic features (A') to (E') of the present invention can be detected.
- the probe of the present invention preferably has a label.
- Non-limiting examples of such labels include fluorescent labels, luminescent labels, radioactive labels, dyes, enzymes, quenchers, binding moieties with detectable labels, and the like.
- the probe of the invention comprises a base sequence complementary to a base sequence selected from SEQ ID NOs: 17-19, 21-23, 25-27, 29-31, 33-35, 66-80. It has a polynucleotide and a label.
- the present invention further provides a kit comprising the above primer set and a corresponding restriction enzyme.
- the kit of the invention comprises the primer sets set forth in Tables 1-5 above and the corresponding restriction enzymes.
- the present invention also relates to a primer set capable of amplifying a region having a base sequence selected from the group consisting of the above SEQ ID NOs: 1 to 5, 16, 20, 24, 28 and 32 by PCR, and the corresponding above-mentioned book.
- a kit containing the probe of the invention is provided.
- primer sets, probes and kits can be used for detecting the genetic features of the present invention, used for the screening method of the present invention, and the like.
- these primer sets and kits include instructions including detection of genetic features of the present invention and explanations of the screening method of the present invention, such as instructions for use and site information (eg, information on how to use). , URL, two-dimensional code), a medium on which information on usage is recorded (for example, a flexible disc, a CD, a DVD, a Blu-ray disc, a memory card, a USB memory) and the like may be included.
- the invention provides a screening kit for Stevia plants of the invention, comprising a reagent for detecting the presence and / or absence of at least one of the genetic features (A)-(E).
- Reagents may include primers and / or probes used in the CAPS, dCAPS or TaqMan PCR methods.
- the reagent for detecting the presence and / or absence of at least one of the genetic features (A) to (E) dCAPS at least one of the above genetic features (A) to (E).
- a combination of a primer set and a restriction enzyme for detection by a method for example, a combination of a primer set and a restriction enzyme shown in Tables 1 to 5, or a mutation site of the present invention that can be used in the TaqMan PCR method or the like.
- a primer set for amplifying for example, a site containing a sequence selected from SEQ ID NOs: 16 to 35
- a site related to at least one of the genetic features (A) to (E) for example, SEQ ID NOs: 17-19,
- a site containing a sequence selected from 21-23, 25-27, 29-31, 33-35 includes a combination with a probe having a complementary base sequence.
- a method for producing a plant-derived RebE-containing extract, the extract and a product using the extract In a further aspect of the present invention, the plant of the present invention, the Stevia plant selected by the screening method of the present invention, or the present invention.
- RebE-containing extract comprising the step of obtaining a RebE-containing extract from a Stevia plant produced by the production method of the above, or seeds, leaves (for example, dried leaves or fresh leaves), tissues, tissue cultures or cells of the plant.
- a method for producing a product hereinafter, may be referred to as "method for producing a RevE-containing extract of the present invention" is provided.
- the plant of the present invention the Stevia plant selected by the screening method of the present invention, the Stevia plant produced by the production method of the present invention, or the seeds, leaves (for example, dried leaves or fresh leaves) of the plant.
- a RebE-containing extract from a tissue, tissue culture or cell (hereinafter, may be referred to as "RebE-containing extract of the present invention”).
- the RebE-containing extract of the present invention is preferably produced by the method for producing a RebE-containing extract of the present invention.
- a method for producing RebE hereinafter, may be referred to as "method for producing RebE of the present invention" including a step of purifying RebE from the RebE-containing extract of the present invention is provided.
- the method for producing RebE of the present invention comprises a step of obtaining an extract containing RebE from the plant of the present invention, the Stevia plant selected by the screening method of the present invention, or the Stevia plant produced by the production method of the present invention. Further may be included.
- the RebE-containing extract can be obtained, for example, by reacting the fresh or dried leaves of the plant of the present invention with an appropriate solvent (an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone).
- an appropriate solvent an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone.
- the method described in Ohta et al. Or WO2010 / 038911 described above and the method described in Examples described later can be referred to.
- RebE-containing extract can also be purified by using a known method such as high performance liquid chromatography (UPLC).
- HPLC high performance liquid chromatography
- TOF-MS time-of-flight mass spectrum
- UPLC high performance liquid chromatography
- the RebE-containing extract of the present invention contains a higher content of RebE than the RebE-containing extract obtained from a Stevia species having no genetic characteristics of the present invention.
- the RebE-containing extract of the present invention has more than 100% RebE, 105% or more, 109% or more, 150% or more, 200% as compared with the RebE-containing extract from a Stevia plant having no genetic characteristics of the present invention.
- the upper limit is not particularly limited, but may be, for example, 21000% or less, 18000% or less, and the like.
- the RebE-containing extract of the present invention and the RebE-containing extract obtained from a Stevia plant having no genetic characteristics of the present invention may be obtained by the same method.
- Sweetening compositions, flavors or pharmaceuticals can be produced. Therefore, another embodiment of the present invention is to eat and drink the RebE-containing extract of the present invention and / or the step of providing RebE obtained by the method for producing RebE of the present invention, and such an extract and / or RebE.
- a method for producing a food or drink, a sweetening composition, a fragrance or a pharmaceutical product which comprises a step of adding the product, a sweetening composition, a fragrance or a pharmaceutical product.
- the present invention provides a novel food or drink, a sweetening composition, a flavor or a pharmaceutical product obtained by the above-mentioned production method and having an increased content of RevE.
- food and drink means beverages and foods.
- the present invention provides a novel beverage, food, sweetening composition, flavor or pharmaceutical, and also provides a method for producing the beverage, food, sweetening composition, flavor or pharmaceutical.
- the present invention provides, in another embodiment, the nucleotide sequence of the plant of the present invention.
- the base sequence relating to the Stevia plant having the genetic feature (A) contains or consists of a base sequence selected from SEQ ID NOs: 16-19.
- the base sequence relating to the Stevia plant having the genetic feature (B) includes or consists of a base sequence selected from SEQ ID NOs: 20 to 23.
- the base sequence relating to the Stevia plant having the genetic feature (C) includes or consists of a base sequence selected from SEQ ID NOs: 24-27.
- the base sequence relating to the Stevia plant having the genetic feature (D) includes or consists of a base sequence selected from SEQ ID NOs: 28 to 31.
- the base sequence relating to the Stevia plant having the genetic feature (E) includes or consists of a base sequence selected from SEQ ID NOs: 32 to 35.
- Example 1 Preparation of high RebE Stevia plant
- the present inventors repeated selection and mating of Stevia plants in order to obtain a Stevia plant containing a large amount of RebD.
- the specific procedure is as follows.
- test line Wild-type Stevia seeds (commercially available varieties) were treated with ethyl methanesulfonic acid (EMS) and sown and cultivated in the greenhouse in the Suntory World Research Center. An appropriate amount of fresh leaves were sampled from each grown individual, and the concentration of RebD was quantified by LC-MS / MS (Shimadzu LCMS8050). Specifically, 0.25 g of fresh leaves were dried by freeze-drying, and 0.05 g of the crushed dried product was put into 100 times the amount (5 mL) of pure water. Extracted by ultrasonic treatment for 20 minutes, centrifuged and filtered, and then diluted 60-fold with 32% acetonitrile to prepare a sample solution.
- EMS ethyl methanesulfonic acid
- LC-MS / MS analysis was performed on 1 mL of this sample solution in the MRM mode of LCMS8050, the concentration of RebD was quantified, and individuals having a concentration of 2% or more were selected and mated to obtain seeds. Such selection was repeated for 4 generations to obtain populations A and B of the 4th generation (S4 generation) of hybrids.
- S42-1 to S42-78 of the population B contained an amount of RebE exceeding 0.06% by mass on a dry leaf basis, that is, a large amount of RebE. Further, among them, S42-1 to S42-29 contained an amount of RebE exceeding 0.49% by mass on a dry leaf basis, that is, a particularly large amount of RebE.
- Example 2 Detection of genetic characteristics peculiar to high RevE Stevia plants Genomic DNA was extracted from the fresh leaves of some of the individuals tested in Example 1, and the genetic characteristics were characterized by a sequencer (HiSeq 2500, Illumina). Analysis was carried out. As a result, there was a tendency for genetic features (A) to (E) to be detected in strains with a high RebE content. Therefore, in order to improve the efficiency of detection of genetic features, dCAPS primers for detecting genetic features (A) were prepared, and the presence or absence of these genetic features was evaluated for the remaining individuals by the dCAPS method.
- the detection of genetic characteristics by the dCAPS method was performed as follows. First, genomic DNA was extracted from the fresh leaves of each individual tested in Example 1, PCR was performed using the above dCAPS primer corresponding to each genetic feature, the above restriction enzyme was added to the PCR product, and the temperature was 37 ° C. An enzymatic reaction was performed. Electrophoresis of the restriction enzyme-treated product was performed with a microchip-type electrophoresis device LabChip GX Touch HT (PerkinElmer), and the presence or absence of genetic features was determined based on the obtained band pattern.
- A' is an individual in which only a non-degradable band is observed
- A'' is an individual in which both a degradation product and a non-degradable band are observed
- Strains with the genetic feature (A') of the present invention have a particularly high RebE content (mean about 2.98%, up to 4.16% in population A; average about 2.79%, up to 3 in population B). .52%).
- the strains having the genetic characteristics of the present invention tend to have a high mass ratio of RebE to TSG (minimum 2.4%, maximum 45.8% in population A, minimum 1.5%, maximum in population B). 39.3%), strains with the genetic feature (A') of the invention tended to have a particularly high mass ratio of RebE to TSG (minimum 25.5%, maximum 45.8% in population A). . Minimum 22.4%, maximum 39.3% in group B).
- the strain having the genetic characteristics of the present invention has a RebE content of 1 or less with respect to stevioside (0.11 to 0.85 in the group A and 0.07 to 0.65 in the group B), and the genetic characteristics of the present invention.
- the strains having (A') had a RebE content of 0.07 to 0.85 for stevioside (0.35 to 0.85 in group A and 0.29 to 0.65 in group B).
- the present invention makes it possible to more efficiently provide useful steviol glycosides such as ReE, provision of high-quality beverages, foods, sweetening compositions, flavors, pharmaceuticals and the like containing such steviol glycosides. Can be promoted.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
[1]以下の(A)~(E)の遺伝的特徴の少なくとも1つを有する、ステビア植物体。
(A)配列番号1の40位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(B)配列番号2の21位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(C)配列番号3の28位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(D)配列番号4の59位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(E)配列番号5の64位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
[2]乾燥葉の単位質量当たり0.07%以上のレバウジオシドEを含む、上記[1]に記載の植物体。
[3]非遺伝子組換ステビア植物体である、上記[1]又は[2]に記載の植物体。
[4]変異誘発処理を行ったステビア植物体及びその子孫植物体を含む、上記[1]~[3]のいずれかに記載の植物体。
[5]上記[1]~[4]のいずれかに記載の植物体の種子、乾燥葉、組織、組織培養物又は細胞。
[6]胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルスから選択される、上記[5]に記載の組織、組織培養物又は細胞。
[7]上記[1]~[4]のいずれかに記載のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、乾燥葉の単位質量あたり0.07%以上のレバウジオシドEを含むことを特徴とする、高レバウジオシドE含有ステビア植物体を作出する方法。
[8]第2の植物体が上記[1]~[4]のいずれかに記載のステビア植物体である、上記[7]に記載の方法。
[9]レバウジオシドEを含む、上記[1]~[4]のいずれかに記載の植物体、上記[5]に記載の種子、乾燥葉、組織、組織培養物又は細胞の抽出物。
[10]上記[9]に記載の抽出物を含む飲食品、甘味料組成物、香料又は医薬品。
[11]上記[1]~[4]のいずれかに記載の植物体、上記[5]に記載の種子、乾燥葉、組織、組織培養物又は細胞からレバウジオシドE含有抽出物を得る工程を含む、レバウジオシドE含有抽出物の製造方法。
[12]上記[11]に記載のレバウジオシドE含有抽出物からレバウジオシドEを精製する工程を含む、レバウジオシドEの製造方法。
[13]上記[1]~[4]のいずれかに記載の植物体の抽出物、上記[5]に記載の種子、乾燥葉、組織、組織培養物又は細胞の抽出物、或いは、上記[11]に記載の抽出物を提供する工程、及び
前記抽出物を、飲食品、甘味料組成物、香料又は医薬品の原料に添加する工程
を含む、飲食品、甘味料組成物、香料又は医薬品の製造方法。
[14]被験植物のゲノムから、以下の(A)~(E)の遺伝的特徴の少なくとも1つの存在及び/又は不在を検出する工程を含む、上記[1]~[4]のいずれかに記載のステビア植物体をスクリーニングする方法。
(A)配列番号1の40位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(B)配列番号2の21位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(C)配列番号3の28位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(D)配列番号4の59位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(E)配列番号5の64位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
[15]さらに、葉組織のレバウジオシドEの含有量を測定する工程を含む、上記[14]に記載の方法。
[16]スクリーニングにより得られる植物体が、乾燥葉の単位質量あたり0.07%以上のレバウジオシドEを含む、上記[14]又は[15]に記載の方法。
なお、本明細書において引用した全ての文献、及び公開公報、特許公報その他の特許文献は、参照として本明細書に組み込むものとする。また、本明細書は、2020年5月12日に出願された本願優先権主張の基礎となる日本国特許出願(特願2020-084130号)の明細書及び図面に記載の内容を包含する。
本発明は、野生種のステビア植物体から派生し、以下の(A)~(E)の遺伝的特徴の少なくとも1つ(以下、遺伝的特徴(A)~(E)の少なくとも1つを「本発明の遺伝的特徴」と総称する場合がある)を有するステビア植物体(以下、「本発明の植物体」又は「本発明のステビア植物体」と総称する場合がある)を提供する。(A)配列番号1の40位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である(以下、「本発明の遺伝的特徴(A)」と称する場合がある)。
(B)配列番号2の21位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である(以下、「本発明の遺伝的特徴(B)」と称する場合がある)。
(C)配列番号3の28位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である(以下、「本発明の遺伝的特徴(C)」と称する場合がある)。
(D)配列番号4の59位に相当する塩基がCであるアレルについてホモ接合性又はヘテロ接合性である(以下、「本発明の遺伝的特徴(D)」と称する場合がある)。
(E)配列番号5の64位に相当する塩基がTであるアレルについてホモ接合性又はヘテロ接合性である(以下、「本発明の遺伝的特徴(E)」と称する場合がある)。
本発明の遺伝的特徴(C)としては、配列番号3の28位に相当する位置の塩基がTであるアレルについてホモ接合性である遺伝的特徴(以下、「本発明の遺伝的特徴(C’)」と称する場合がある。)が好適である。なお、配列番号3の28位に相当する位置の塩基がTであるアレルについてヘテロ接合性である遺伝的特徴を、本発明の遺伝的特徴(C’’)と称する場合がある。
本発明の遺伝的特徴(D)としては、配列番号4の59位に相当する位置の塩基がCであるアレルについてホモ接合性である遺伝的特徴(以下、「本発明の遺伝的特徴(D’)」と称する場合がある。)が好適である。なお、配列番号4の59位に相当する位置の塩基がCであるアレルについてヘテロ接合性である遺伝的特徴を、本発明の遺伝的特徴(D’’)と称する場合がある。
本発明の遺伝的特徴(E)としては、配列番号5の64位に相当する位置の塩基がTであるアレルについてホモ接合性である遺伝的特徴(以下、「本発明の遺伝的特徴(E’)」と称する場合がある。)が好適である。なお、配列番号5の64位に相当する位置の塩基がTであるアレルについてヘテロ接合性である遺伝的特徴を、本発明の遺伝的特徴(E’’)と称する場合がある。
ここでは簡潔のため本発明の遺伝的特徴(A)を例に説明したが、本発明の遺伝的特徴(B)~(E)についても同様である。
特定の態様において、「配列番号2に相当する塩基配列からなる部分」には、例えば、配列番号8の塩基配列を含むフォワードプライマーと、配列番号9の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物体のゲノムの部分が含まれる。
特定の態様において、「配列番号3に相当する塩基配列からなる部分」には、例えば、配列番号10の塩基配列を含むフォワードプライマーと、配列番号11の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物体のゲノムの部分が含まれる。
特定の態様において、「配列番号4に相当する塩基配列からなる部分」には、例えば、配列番号12の塩基配列を含むフォワードプライマーと、配列番号13の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物体のゲノムの部分が含まれる。
特定の態様において、「配列番号5に相当する塩基配列からなる部分」には、例えば、配列番号14の塩基配列を含むフォワードプライマーと、配列番号15の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物体のゲノムの部分が含まれる。
特定の態様において、「配列番号2の21位に相当する位置の塩基がTであるアレル」は、配列番号20、21、22又は23の塩基配列を含む。
特定の態様において、「配列番号3の28位に相当する位置の塩基がTであるアレル」は、配列番号24、25、26又は27の塩基配列を含む。
特定の態様において、「配列番号4の59位に相当する位置の塩基がCであるアレル」は、配列番号28、29、30又は31の塩基配列を含む。
特定の態様において、「配列番号5の64位に相当する位置の塩基がTであるアレル」は、配列番号32、33、34又は35の塩基配列を含む。
候補植物体が変異(A)を有する場合、例えば、候補植物体のゲノムDNAに対し、配列番号36に示す塩基配列を有するフォワードプライマー及び配列番号37に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(約203bp長、例えば配列番号38)を制限酵素RsaIで処理しても約203bp長のバンド(例えば、配列番号38)しか得られない。一方、候補植物体が変異(A)を有しない(配列番号1の40位に相当する位置の塩基がTである)場合、上記と同様にPCR増幅を行い、得られたPCR産物(約203bp長、例えば、配列番号39)を制限酵素RsaIで処理すると、約40bp長のバンド(例えば、配列番号40)と約163bp長のバンド(例えば、配列番号41)が得られる。上記手法により変異(A)を検出した例を図7に示す。レーン1には変異(A)を有するアレルについてホモ接合性のステビア個体、レーン2には変異(A)を有するアレルについてヘテロ接合性のステビア個体、レーン3には変異(A)を有しないアレルについてホモ接合性のステビア個体のDNAを制限酵素RsaIで処理したサンプルをそれぞれ負荷した。レーン1には、酵素により分解されなかった約203bp長のバンドが認められる。レーン2には、酵素により分解された約40bp長のバンドと約163bp長のバンド、及び、酵素により分解されなかった約203bp長のバンドが認められる。したがって、上記のdCAPS法により、非分解物に由来する約203bp長のバンドが認められた場合、本発明の遺伝的特徴(A)を有すると決定することができる。分解物に由来する約40bp長のバンド及び/又は約163bp長のバンドが認められず、非分解物に由来する約203bp長のバンドが認められた場合、本発明の遺伝的特徴(A’)を有すると決定することができる。分解物に由来する約40bp長のバンド及び/又は約163bp長のバンドと、非分解物に由来する約203bp長のバンドとが認められた場合、本発明の遺伝的特徴(A’’)を有すると決定することができる。
ここで乾燥葉とは、本発明のステビア植物体の新鮮葉を乾燥させることにより含水量を3~4重量%にまで減らしたものをいう。
さらに、このようにして得られた抽出液に対し、酢酸エチルその他の有機溶媒:水の勾配、高速液体クロマトグラフィー(High Performance Liquid Chromatography:HPLC)、ガスクロマトグラフィー、飛行時間型質量分析(Time-of-Flight mass spectrometry:TOF-MS)、超高性能液体クロマトグラフィー(Ultra (High) Performance Liquid chromatography:UPLC)等の公知の方法を用いることにより個々のステビオール配糖体、例えばRebEを精製することができる。
一般に、植物細胞は、培養の間に変異を伴うことがあるため、より安定した形質維持のために植物個体に戻すことが好ましい。
本発明の植物体を宿主として事後的に遺伝子組み換え(例えばゲノム編集等により)を行って得られた植物体(例えば、本発明の植物体を宿主として遺伝子組み換えを行って、さらに別の形質を付加した植物体)も、本発明の範囲から除外されるものではない。
本発明の植物体の再生可能な形態の例としては、胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルス等が挙げられるが、これらに限定されるものではない。
本発明は、別の実施態様において、本発明のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、乾燥葉あたり0.07質量%以上のRebEを含むことを特徴とする、ステビア植物体を作出する方法(以下、「本発明の作出方法」と称する場合がある)を提供する。当該方法により作出されるステビア植物体は、本発明の植物体と同じ表現型と遺伝的特徴を有する。
本発明の植物体及び本発明の植物体と同じ表現型及び/又は遺伝的特徴を有する植物体は、当該植物体の組織から本発明の遺伝的特徴を検出することによりスクリーニングすることができる。ここで、「スクリーニング」とは、本発明の植物体とそれ以外の植物体とを識別し、本発明の植物体を選択することを意味する。
したがって、本発明は、別の側面において、被験植物体のゲノムから本発明の遺伝的特徴(A)~(E)の少なくとも1つの存在及び/又は不在を検出する工程を含む、ステビア植物体をスクリーニングする方法(以下、「本発明のスクリーニング方法」と称する場合がある)を提供する。
本発明のスクリーニング方法は、上記の少なくとも1つの遺伝的特徴の存在が検出された植物体を被験植物体の中から選択する工程をさらに含んでもよい。
(I)配列番号1の40位に相当する位置の塩基がCであるアレル(例えば、配列番号16、17、18又は19の塩基配列を含むアレル、以下、「アレルa」と称することがある)の存在、
(II)配列番号2の21位に相当する位置の塩基がTであるアレル(例えば、配列番号20、21、22又は23の塩基配列を含むアレル、以下、「アレルb」と称することがある)の存在、
(III)配列番号3の28位に相当する位置の塩基がTであるアレル(例えば、配列番号24、25、26又は27の塩基配列を含むアレル、以下、「アレルc」と称することがある)の存在、
(IV)配列番号4の59位に相当する位置の塩基がCであるアレル(例えば、配列番号28、29、30又は31の塩基配列を含むアレル、以下、「アレルd」と称することがある)の存在、及び/又は
(V)配列番号5の64位に相当する位置の塩基がTであるアレル(例えば、配列番号32、33、34又は35の塩基配列を含むアレル、以下、「アレルe」と称することがある)の存在
により決定することができる。
(i)配列番号1の40位に相当する位置の塩基がTであるアレル(例えば、配列番号1、66、67又は68の塩基配列を含むアレル、以下、「アレルA」と称することがある)のみの存在、
(ii)配列番号2の21位に相当する位置の塩基がAであるアレル(例えば、配列番号2、69、70又は71の塩基配列を含むアレル、以下、「アレルB」と称することがある)のみの存在、
(iii)配列番号3の28位に相当する位置の塩基がCであるアレル(例えば、配列番号3、72、73又は74の塩基配列を含むアレル、以下、「アレルC」と称することがある)のみの存在、
(iv)配列番号4の59位に相当する位置の塩基がAであるアレル(例えば、配列番号4、75、76又は77の塩基配列を含むアレル、以下、「アレルD」と称することがある)のみの存在、及び/又は
(v)配列番号5の64位に相当する位置の塩基がCであるアレル(例えば、配列番号5、78、79又は80の塩基配列を含むアレル、以下、「アレルE」と称することがある)のみの存在、
により決定することができる。
本発明の遺伝的特徴(B’)の存在は、例えば、アレルbのみの存在により決定することができる。遺伝的特徴(B’’)の存在は、例えば、アレルbとアレルBの両方の存在により決定することができる。
本発明の遺伝的特徴(C’)の存在は、例えば、アレルcのみの存在により決定することができる。遺伝的特徴(C’’)の存在は、例えば、アレルcとアレルCの両方の存在により決定することができる。
本発明の遺伝的特徴(D’)の存在は、例えば、アレルdのみの存在により決定することができる。遺伝的特徴(D’’)の存在は、例えば、アレルdとアレルDの両方の存在により決定することができる。
本発明の遺伝的特徴(E’)の存在は、例えば、アレルeのみの存在により決定することができる。遺伝的特徴(E’’)の存在は、例えば、アレルeとアレルEの両方の存在により決定することができる。
本発明の遺伝的特徴(B’)の不在は、例えば、アレルBの存在により決定することができる。遺伝的特徴(B’’)の不在は、例えば、アレルBかアレルbのいずれか一方のみの存在により決定することができる。
本発明の遺伝的特徴(C’)の不在は、例えば、アレルCの存在により決定することができる。遺伝的特徴(C’’)の不在は、例えば、アレルCかアレルcのいずれか一方のみの存在により決定することができる。
本発明の遺伝的特徴(D’)の不在は、例えば、アレルDの存在により決定することができる。遺伝的特徴(D’’)の不在は、例えば、アレルDかアレルdのいずれか一方のみの存在により決定することができる。
本発明の遺伝的特徴(E’)の不在は、例えば、アレルEの存在により決定することができる。遺伝的特徴(E’’)の不在は、例えば、アレルEかアレルeのいずれか一方のみの存在により決定することができる。
或いは、本発明の変異とプライマー配列とは重複させず、かつ本発明の遺伝子変異をPCR増幅させることが可能なようにプライマー配列を設計し、増幅されたヌクレオチド断片の塩基配列をシーケンスすることにより、本発明の遺伝的特徴を検出することができる。
PCR及びアガロースゲル電気泳動については、以下を参照:Sambrook, Fritsch and Maniatis, ”Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press。
シーケンス法とは、変異を含む領域をPCRにて増幅させ、Dye Terminator等を用いてDNA配列をシーケンスすることで、変異の有無を解析する方法である(Sambrook, Fritsch and Maniatis, ”Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press)。
DNAマイクロアレイは、ヌクレオチドプローブの一端が支持体上にアレイ状に固定されたものであり、DNAチップ、Geneチップ、マイクロチップ、ビーズアレイ等を包含する。本発明の変異部位と相補的な配列を含むプローブを用いることで、網羅的に本発明の多型の有無を検出することができる。DNAチップ等のDNAマイクロアレイアッセイとしてはGeneChipアッセイが挙げられる(Affymetrix社;米国特許第6,045,996号、同第5,925,525号、及び同第5,858,659号参照)。GeneChip技術は、チップに貼り付けたオリゴヌクレオチドプローブの小型化高密度マイクロアレイを利用するものである。
TILLING(Targeting Induced Local Lesions IN Genomes)法とは、変異導入した突然変異体集団のゲノム中の変異ミスマッチをPCR増幅とCEL Iヌクレアーゼ処理によってスクリーニングする方法である。
・プライマーセット:
配列番号36の3’末端から15~39塩基長の連続する配列を含むフォワードプライマーと、配列番号1又は16の41位より3’側に位置する任意の連続する15塩基以上の配列に相補的な配列(例えば、配列番号37)を含むリバースプライマーとを含むプライマーセット、又は、配列番号81又は82の3’末端から15~20塩基長の連続する配列を含むフォワードプライマーと、配列番号83又は84の22位より3’側に位置する任意の連続する15塩基以上の配列に相補的な配列(例えば、配列番号85)を含むリバースプライマーを含むプライマーセット。
・制限酵素:
配列番号36に基づくプライマーセットに対応する制限酵素はRsaI、配列番号81に基づくプライマーセットに対応する制限酵素はTsp45I、配列番号82に基づくプライマーセットに対応する制限酵素はAciIをそれぞれ含む。
・プライマーセット:
配列番号42、86又は87の3’末端から15~20塩基長の連続する配列を含むフォワードプライマーと、配列番号2又は20の22位より3’側に位置する任意の連続する15塩基以上の配列に相補的な配列(例えば、配列番号43)を含むリバースプライマーを含むプライマーセット。
・制限酵素:
配列番号42に基づくプライマーセットに対応する制限酵素はAclI、配列番号86に基づくプライマーセットに対応する制限酵素はAluI、配列番号87に基づくプライマーセットに対応する制限酵素はPacIをそれぞれ含む。
・プライマーセット:
配列番号48、88又は89の3’末端から15~20塩基長の連続する配列を含むフォワードプライマーと、配列番号50又は51の22位より3’側に位置する任意の連続する15塩基以上の配列に相補的な配列(例えば、配列番号49)を含むリバースプライマーとを含むプライマーセット。
・制限酵素:
配列番号48に基づくプライマーセットに対応する制限酵素はAluI、配列番号88に基づくプライマーセットに対応する制限酵素はBglI、配列番号89に基づくプライマーセットに対応する制限酵素はScaIをそれぞれ含む。
・プライマーセット:
配列番号54、90又は91の3’末端から15~21塩基長の連続する配列を含むフォワードプライマーと、配列番号56又は57の23位より3’側に位置する任意の連続する15塩基以上の配列に相補的な配列(例えば、配列番号55)を含むリバースプライマーとを含むプライマーセット。
・制限酵素:
配列番号54に基づくプライマーセットに対応する制限酵素はAluI、配列番号90に基づくプライマーセットに対応する制限酵素はMboI、配列番号91に基づくプライマーセットに対応する制限酵素はBglIIをそれぞれ含む。
・プライマーセット:
配列番号60、92又は93の3’末端から15~22塩基長の連続する配列を含むフォワードプライマーと、配列番号62又は63の24位より3’側に位置する任意の連続する15塩基以上の配列に相補的な配列(例えば、配列番号61)を含むリバースプライマーとを含むプライマーセット。
・制限酵素:
配列番号60に基づくプライマーセットに対応する制限酵素はAluI、配列番号92に基づくプライマーセットに対応する制限酵素はMboI、配列番号93に基づくプライマーセットに対応する制限酵素はBglIIをそれぞれ含む。
(i)本発明の遺伝的特徴が検出された被験ステビア植物組織(例えば葉)のRebEの含有量を測定する工程、
(ii)本発明の遺伝的特徴が検出された被験ステビア植物体のうち、RebEの含有量が高い個体を選択する工程、
(iii)選択したRebEの含有量が高い個体を他のステビア植物体と交配する工程、
(iv)交配により得られた子植物体のゲノムから、本発明の遺伝的特徴を検出する工程、
(v)本発明の遺伝的特徴が検出された子植物組織のRebEの含有量を測定する工程、
(vi)本発明の遺伝的特徴が検出された子植物体のうち、RebEの含有量が高い個体を選択する工程。
(i’)本発明の遺伝的特徴が検出された被験ステビア植物組織(例えば葉)のステビオシド又はTSGの含有量を測定する工程、
(ii’)本発明の遺伝的特徴が検出された被験ステビア植物体のうち、RebE/ステビオシド又はTSGに対するRebEの質量比が高い個体を選択する工程、
(iii’)選択したRebE/ステビオシド又はTSGに対するRebEの質量比が高い個体を他のステビア植物体と交配する工程、
(iv’)交配により得られた子植物体のゲノムから、本発明の遺伝的特徴を検出する工程、
(v’)本発明の遺伝的特徴が検出された子植物組織のステビオシド又はTSGの含有量を測定する工程、
(vi’)本発明の遺伝的特徴が検出された子植物体のうち、RebE/ステビオシド又はTSGに対するRebEの質量比が高い個体を選択する工程。
本発明のスクリーニング方法において、被験ステビア植物体は、変異誘発処理を行ったステビア植物体及びその子孫植物体を含んでもよい。変異の誘発については、本発明の植物体の項に記載したとおりであり、変異誘発剤による処理や、放射線又は光線の照射による処理等を含む。
本発明はまた、上記の配列番号1~5、16、20、24、28及び32からなる群から選択される塩基配列を有する領域をPCRにより増幅し得るプライマーセットと、それに対応する上記の本発明のプローブとを含むキットを提供する。
本発明のさらなる態様において、本発明の植物体、本発明のスクリーニング方法により選別されたステビア植物体若しくは本発明の作出方法により製造されたステビア植物体、又は当該植物体の種子、葉(例えば、乾燥葉又は新鮮葉)、組織、組織培養物若しくは細胞からRebE含有抽出物を得る工程を含む、RebE含有抽出物の製造方法(以下、「本発明のRebE含有抽出物の製造方法」と称する場合がある)が提供される。
本発明のRebE含有抽出物は、本発明の遺伝的特徴を有しないステビア植物体からのRebE含有抽出物と比べRebEを100%より多い、105%以上、109%以上、150%以上、200%以上、210%以上、290%以上、400%以上、600%以上、800%以上、1000%以上、1200%以上、1300%以上、1400%以上、1500%以上、1600%以上、1700%以上、1800%以上、1900%以上、2000%以上、2100%以上、2200%以上、2300%以上、2400%以上、2500%以上、2600%以上、2700%以上、2800%以上、2900%以上、3000%以上、3100%以上、3200%以上、3300%以上、3400%以上、3500%以上、3600%以上、3700%以上、3800%以上、3900%以上、4000%以上、4100%以上、4200%以上、4300%以上、4400%以上、4500%以上、4600%以上、4700%以上、4800%以上、4900%以上、5000%以上高い含量で含んでいてもよい。上限は、特に制限されないが、例えば21000%以下、18000%以下等であってよい。ここで、本発明のRebE含有抽出物と、本発明の遺伝的特徴を有しないステビア植物体から得られたRebE含有抽出物は、同じ方法で得られたものであってよい。
本発明は、別の態様において、本発明の植物体に係る塩基配列を提供する。
遺伝的特徴(A)を有するステビア植物体に係る塩基配列は、配列番号16~19から選択される塩基配列を含む、又はそれからなる。遺伝的特徴(B)を有するステビア植物体に係る塩基配列は、配列番号20~23から選択される塩基配列を含む、又はそれからなる。遺伝的特徴(C)を有するステビア植物体に係る塩基配列は、配列番号24~27から選択される塩基配列を含む、又はそれからなる。遺伝的特徴(D)を有するステビア植物体に係る塩基配列は、配列番号28~31から選択される塩基配列を含む、又はそれからなる。遺伝的特徴(E)を有するステビア植物体に係る塩基配列は、配列番号32~35から選択される塩基配列を含む、又はそれからなる。
本発明者らは、RebDを多く含有するステビア植物体を得るべく、ステビア植物体の選別と交配を繰り返した。その過程で、RebEを多く含有するステビア植物体の存在に気づいた。具体的な手順は以下のとおりである。
野生型ステビア種子(市販品種)に対してエチルメタンスルホン酸(EMS)処理を行い、これをサントリーワールドリサーチセンター内温室にて播種、栽培した。成長した各個体より適量の新鮮葉をサンプリングし、LC-MS/MS(島津LCMS8050)にてRebDの濃度を定量した。具体的には、0.25gの新鮮葉をフリーズドライにより乾燥し、破砕乾物0.05gを100倍量(5mL)の純水中に投入した。超音波処理20分にて抽出し、遠心・濾過した後、32%アセトニトリルで60倍希釈したものをサンプル液とした。このサンプル液1mLをLCMS8050のMRMモードにてLC-MS/MS分析を行い、RebDの濃度を定量し、その濃度が2%以上の個体を選別して交配し、種子を得た。このような選別を4世代にわたって繰り返し、雑種第4代(S4世代)の集団A及びBを得た。
集団A及びBの各個体より適量の新鮮葉をサンプリングし、上記1.と同様にLC-MS/MS分析を行い、RebA、RebB、RebC、RebD、RebE、RebF、RebG、RebM、RebN及びステビオシド(STV)の濃度(乾燥葉に対する質量%)を定量し、その合計をTSG濃度とした。結果を下表に示す。なお、表中の各値は、ステビア植物体一個体の測定値である。
上記結果が示すとおり、集団AのうちS41-1~S41-73は、乾燥葉ベースで0.10質量%を超える量のRebEを含んでおり、すなわち、RebEを多く含んでいた。そのうち、S41-1~S41-22は、乾燥葉ベースで0.62質量%を超える量のRebEを含んでおり、すなわち、特に多くのRebEを含んでいた。
上記結果が示すとおり、集団BのうちS42-1~S42-78は、乾燥葉ベースで0.06質量%を超える量のRebEを含んでおり、すなわち、RebEを多く含んでいた。さらに、そのうちS42-1~S42-29は、乾燥葉ベースで0.49質量%を超える量のRebEを含んでおり、すなわち、RebEを特に多く含んでいた。
実施例1で試験した一部の個体の新鮮葉からゲノムDNAを抽出し、シーケンサー(HiSeq 2500、Illumina)により遺伝的特徴の分析を行った。
その結果、RebE含量の高い系統で遺伝的特徴(A)~(E)が検出される傾向がみられた。そこで、遺伝的特徴の検出を効率化すべく、遺伝的特徴(A)を検出するためのdCAPSプライマーを作製し、残りの個体についてこれらの遺伝的特徴の有無をdCAPS法により評価した。なお、遺伝的特徴(B)~(E)については、変異部位が遺伝的特徴(A)のものとゲノム上の位置が近く、連鎖不平衡の状態にあると考えられたため、dCAPS法による検討は省略した。
上記結果から明らかなように、本発明の遺伝的特徴を有する系統は、RebE含量が高い傾向にある(集団Aにおいて平均約1.13%、最大4.16%。集団Bにおいて平均約1.17%、最大3.52%)。本発明の遺伝的特徴(A’)を有する系統は、特にRebE含有量が高い(集団Aにおいて平均約2.98%、最大4.16%。集団Bにおいて平均約2.79%、最大3.52%)。
本発明の遺伝的特徴を有する系統は、TSGに対するRebEの質量比が高い傾向にあり(集団Aにおいて、最小2.4%、最大45.8%。集団Bにおいて、最小1.5%、最大39.3%)、本発明の遺伝的特徴(A’)を有する系統は、TSGに対するRebEの質量比が特に高い傾向にあった(集団Aにおいて、最小25.5%、最大45.8%。集団Bにおいて、最小22.4%、最大39.3%)。
本発明の遺伝的特徴を有する系統は、ステビオシドに対するRebE含量が1以下(集団Aにおいて0.11~0.85。集団Bにおいて0.07~0.65)であり、本発明の遺伝的特徴(A’)を有する系統は、ステビオシドに対するRebE含量が0.07~0.85(集団Aにおいて、0.35~0.85。集団Bにおいて、0.29~0.65)であった。
Claims (16)
- 以下の(A)~(E)の遺伝的特徴の少なくとも1つを有する、ステビア植物体。
(A)配列番号1の40位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(B)配列番号2の21位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(C)配列番号3の28位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(D)配列番号4の59位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(E)配列番号5の64位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。 - 乾燥葉の単位質量当たり0.07%以上のレバウジオシドEを含む、請求項1に記載の植物体。
- 非遺伝子組換ステビア植物体である、請求項1又は2に記載の植物体。
- 変異誘発処理を行ったステビア植物体及びその子孫植物体を含む、請求項1~3のいずれか一項に記載の植物体。
- 請求項1~4のいずれか一項に記載の植物体の種子、乾燥葉、組織、組織培養物又は細胞。
- 胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルスから選択される、請求項6に記載の組織、組織培養物又は細胞。
- 請求項1~4のいずれか一項に記載のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、乾燥葉の単位質量あたり0.07%以上のレバウジオシドEを含むことを特徴とする、高レバウジオシドE含有ステビア植物体を作出する方法。
- 第2の植物体が請求項1~4のいずれか一項に記載のステビア植物体である、請求項7に記載の方法。
- レバウジオシドEを含む、請求項1~4のいずれか一項に記載の植物体、請求項5に記載の種子、乾燥葉、組織、組織培養物又は細胞の抽出物。
- 請求項9に記載の抽出物を含む飲食品、甘味料組成物、香料又は医薬品。
- 請求項1~4のいずれか一項に記載の植物体、請求項5に記載の種子、乾燥葉、組織、組織培養物又は細胞からレバウジオシドE含有抽出物を得る工程を含む、レバウジオシドE含有抽出物の製造方法。
- 請求項11に記載のレバウジオシドE含有抽出物からレバウジオシドEを精製する工程を含む、レバウジオシドEの製造方法。
- 請求項1~4のいずれか一項に記載の植物体の抽出物、請求項5に記載の種子、乾燥葉、組織、組織培養物又は細胞の抽出物、或いは、請求項11に記載の抽出物を提供する工程、及び
前記抽出物を、飲食品、甘味料組成物、香料又は医薬品の原料に添加する工程
を含む、飲食品、甘味料組成物、香料又は医薬品の製造方法。 - 被験植物体のゲノムから、以下の(A)~(E)の遺伝的特徴の少なくとも1つの存在及び/又は不在を検出する工程を含む、請求項1~4のいずれか一項に記載のステビア植物体をスクリーニングする方法。
(A)配列番号1の40位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(B)配列番号2の21位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(C)配列番号3の28位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。
(D)配列番号4の59位に相当する位置の塩基がCであるアレルについてホモ接合性又はヘテロ接合性である。
(E)配列番号5の64位に相当する位置の塩基がTであるアレルについてホモ接合性又はヘテロ接合性である。 - さらに、葉組織のレバウジオシドEの含有量を測定する工程を含む、請求項14に記載の方法。
- スクリーニングにより得られる植物体が、乾燥葉の単位質量あたり0.07%以上のレバウジオシドEを含む、請求項14又は15に記載の方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21805155.5A EP4151083A4 (en) | 2020-05-12 | 2021-05-11 | STEVIA PLANT WITH HIGH CONTENT OF REBAUDIOSIDE E |
AU2021271046A AU2021271046A1 (en) | 2020-05-12 | 2021-05-11 | Stevia plant with high content of Rebaudioside E |
PE2022002628A PE20230432A1 (es) | 2020-05-12 | 2021-05-11 | Planta de stevia con alto contenido de rebaudiosido e |
JP2022521941A JPWO2021230258A1 (ja) | 2020-05-12 | 2021-05-11 | |
US17/924,197 US20230180690A1 (en) | 2020-05-12 | 2021-05-11 | Stevia plant with high content of rebaudioside e |
CN202180034250.5A CN115551347A (zh) | 2020-05-12 | 2021-05-11 | 富含瑞鲍迪苷e的甜菊植物体 |
BR112022022876A BR112022022876A2 (pt) | 2020-05-12 | 2021-05-11 | Planta de estévia, semente, folha seca, tecido, cultura de tecido ou célula, métodos para produzir uma planta de estévia com alto teor de rebaudiosídeo e, para produzir um extrato compreendendo rebaudiosídeo e, para produzir rebaudiosídeo e, para produzir um alimento ou bebida, uma composição adoçante, um sabor ou um medicamento e para triagem para a planta de estévia, extrato da planta ou da semente, folha seca, tecido, cultura de tecido ou célula, e, alimento ou bebida, composição adoçante, sabor ou medicamento |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020084130 | 2020-05-12 | ||
JP2020-084130 | 2020-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021230258A1 true WO2021230258A1 (ja) | 2021-11-18 |
Family
ID=78524556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/017955 WO2021230258A1 (ja) | 2020-05-12 | 2021-05-11 | 高レバウジオシドe含有ステビア植物体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230180690A1 (ja) |
EP (1) | EP4151083A4 (ja) |
JP (1) | JPWO2021230258A1 (ja) |
CN (1) | CN115551347A (ja) |
AR (1) | AR122075A1 (ja) |
AU (1) | AU2021271046A1 (ja) |
BR (1) | BR112022022876A2 (ja) |
PE (1) | PE20230432A1 (ja) |
WO (1) | WO2021230258A1 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
JP2002034502A (ja) * | 2000-07-28 | 2002-02-05 | National Institute Of Agrobiological Sciences | 新規ステビア作出方法及び新規ステビア甘味料 |
WO2007070224A2 (en) | 2005-11-23 | 2007-06-21 | The Coca-Cola Company | High-potency sweetener composition with vitamin and compositions sweetened therewith |
WO2010038911A1 (en) | 2008-10-03 | 2010-04-08 | Morita Kagaku Kogyo Co., Ltd. | New steviol glycoside |
US20170283819A1 (en) * | 2014-09-26 | 2017-10-05 | Purecircle Usa Inc. | Single Nucleotide Polymorphism (SNP) Markers for Stevia |
WO2018102648A1 (en) | 2016-12-01 | 2018-06-07 | Purecircle Usa Inc. | Stevia plant and uses thereof |
WO2018124142A1 (ja) * | 2016-12-27 | 2018-07-05 | サントリーホールディングス株式会社 | 高レバウジオシドc含有ステビア植物 |
WO2019074089A1 (ja) * | 2017-10-12 | 2019-04-18 | サントリーホールディングス株式会社 | 高レバウジオシドm含有ステビア植物 |
JP2020084130A (ja) | 2018-11-30 | 2020-06-04 | 東洋インキScホールディングス株式会社 | 複合フィルムからの脱離性を有するラミネート接着剤、積層体、及びシート状基材のリサイクル方法 |
WO2020138364A1 (ja) * | 2018-12-28 | 2020-07-02 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105050388B (zh) * | 2013-03-15 | 2019-08-13 | 嘉吉公司 | 具有提高的莱苞迪苷d含量的甜叶菊植物 |
-
2021
- 2021-05-11 AU AU2021271046A patent/AU2021271046A1/en active Pending
- 2021-05-11 PE PE2022002628A patent/PE20230432A1/es unknown
- 2021-05-11 WO PCT/JP2021/017955 patent/WO2021230258A1/ja unknown
- 2021-05-11 JP JP2022521941A patent/JPWO2021230258A1/ja active Pending
- 2021-05-11 BR BR112022022876A patent/BR112022022876A2/pt unknown
- 2021-05-11 US US17/924,197 patent/US20230180690A1/en active Pending
- 2021-05-11 EP EP21805155.5A patent/EP4151083A4/en active Pending
- 2021-05-11 CN CN202180034250.5A patent/CN115551347A/zh active Pending
- 2021-05-12 AR ARP210101310A patent/AR122075A1/es unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
JP2002034502A (ja) * | 2000-07-28 | 2002-02-05 | National Institute Of Agrobiological Sciences | 新規ステビア作出方法及び新規ステビア甘味料 |
WO2007070224A2 (en) | 2005-11-23 | 2007-06-21 | The Coca-Cola Company | High-potency sweetener composition with vitamin and compositions sweetened therewith |
WO2010038911A1 (en) | 2008-10-03 | 2010-04-08 | Morita Kagaku Kogyo Co., Ltd. | New steviol glycoside |
US20170283819A1 (en) * | 2014-09-26 | 2017-10-05 | Purecircle Usa Inc. | Single Nucleotide Polymorphism (SNP) Markers for Stevia |
WO2018102648A1 (en) | 2016-12-01 | 2018-06-07 | Purecircle Usa Inc. | Stevia plant and uses thereof |
WO2018124142A1 (ja) * | 2016-12-27 | 2018-07-05 | サントリーホールディングス株式会社 | 高レバウジオシドc含有ステビア植物 |
WO2019074089A1 (ja) * | 2017-10-12 | 2019-04-18 | サントリーホールディングス株式会社 | 高レバウジオシドm含有ステビア植物 |
JP2020084130A (ja) | 2018-11-30 | 2020-06-04 | 東洋インキScホールディングス株式会社 | 複合フィルムからの脱離性を有するラミネート接着剤、積層体、及びシート状基材のリサイクル方法 |
WO2020138364A1 (ja) * | 2018-12-28 | 2020-07-02 | サントリーホールディングス株式会社 | 高レバウジオシドd含有ステビア植物 |
Non-Patent Citations (8)
Title |
---|
"Protocols for in vitro cultures and secondary metabolite analysis of aromatic and medicinal plants", METHOD IN MOLECULAR BIOLOGY, vol. 1391, pages 113 - 123 |
LIVAK, K. J., BIOMOL. ENG., vol. 14, 1999, pages 143 - 149 |
LIVAK, K. J., GENET. ANAL., vol. 14, 1999, pages 143 |
LYAMICHEV, V ET AL., SCIENCE, vol. 260, 1993, pages 778 - 783 |
MORRIS T ET AL., J. CLIN. MICROBIOL., vol. 34, 1996, pages 2933 |
OHTA ET AL., J. APPL. GLYCOSCI., vol. 57, no. 3, 2010, pages 199 - 209 |
SAMBROOKFRITSCHMANIATIS: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP4151083A4 |
Also Published As
Publication number | Publication date |
---|---|
AR122075A1 (es) | 2022-08-10 |
AU2021271046A1 (en) | 2022-12-08 |
PE20230432A1 (es) | 2023-03-08 |
CN115551347A (zh) | 2022-12-30 |
EP4151083A4 (en) | 2024-06-26 |
JPWO2021230258A1 (ja) | 2021-11-18 |
US20230180690A1 (en) | 2023-06-15 |
BR112022022876A2 (pt) | 2022-12-20 |
EP4151083A1 (en) | 2023-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3695714A1 (en) | Rebaudioside m-rich stevia plant | |
JP7337068B2 (ja) | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 | |
WO2021230257A1 (ja) | レバウジオシドm含有比の高いステビア植物及びそのスクリーニング方法 | |
JP7520722B2 (ja) | 高レバウジオシドd含有ステビア植物 | |
JP2024012453A (ja) | チラミン低含有ステビア植物 | |
WO2021230256A1 (ja) | 高レバウジオシドd含有ステビア植物 | |
WO2020209265A1 (ja) | 花芽形成能の低いステビア植物 | |
WO2020209266A1 (ja) | 花粉形成能の低いステビア植物 | |
WO2021230258A1 (ja) | 高レバウジオシドe含有ステビア植物体 | |
WO2021230259A1 (ja) | 高ステビオール配糖体含有ステビア植物及びそのスクリーニング方法 | |
WO2024005142A1 (ja) | ステビア植物のスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21805155 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022521941 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022022876 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021271046 Country of ref document: AU Date of ref document: 20210511 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021805155 Country of ref document: EP Effective date: 20221212 |
|
ENP | Entry into the national phase |
Ref document number: 112022022876 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221110 |